BioFirst Corp (6458) registered in Emerging Stock Market (July 15, 2014)

BioFirst Corp (6458) registered in Emerging Stock Market today (July 15). This opens a new dimension in Biotech Industry. BioFirst’s Vitreous Substitute, classified as Class III Medical Device, is going to commence clinical trial, which is also expected to be in leading technological and marketing position after launch, the global market size is over several billion.

“Artificial Vitreous”, also known as “Vitreous Substitute” is exclusively authorized for global market from by NHRI (National Health Research Institute) originally. It is the first hydrogel product used in retinal detachment repair operation in the world, with world-leading technology. It is the “Glory of Taiwan”, BioFirst’s President Dr. Tsung-Shann Jiang addressed. To follow their mission, “honor Glory of Taiwan, Enlighten the window of human soul in the world”, BioFirst obtained exclusive global authorization agreement for most advanced and patented technology from domestic and foreign academic R&D institutions. Biofirst also recruited the expert who invented the original technology to lead the R&D project to ensure the R&D work is sustainable, effective and beneficial. BioFirst received grants from government over last few years, actively invested in R&D to prove this product to meet clinical needs for assisting patients undergone retinal detached disease to regain their vision. This product is currently under GMP production stage, Biofirst will be able to supply global market from their production base in Hsinchu Biomedical Science Park. This outcome originated from Taiwan development, technology, R&D, production to marketing, will increase our country’s awareness, and also encourages the Industry to work together to enter global market.

Under the joint efforts from BioFirst and NHRI, Artificial Vitreous technology has obtained patent approvals in US, Australia and Taiwan. BioFirst also applied to other 10 countries through PCT waiting for approvals, which will provide proper marketing protection.

Capital Securities Corp, who assisted BioFirst registration in Emerging Stock Market addressed, “Biotech Industry will be a major contributor for Taiwan Economy, and advanced medical devices can generate high profit like new drugs, but does not require undergoing phase I (safety), phase II (dosage), or phase III (efficacy) studies, which can proceed efficacy clinical trial directly. This can reduce risk of R&D investment and launch cost. It is a great Industry to participate in. Capital Securities is very excited to promote Biotech Industry with BioFirst Corp, as well as bring investors greater opportunities. During the pre-OTC market trading conference held July 10, the conference room was full, and there were many questions asked during the meeting and discussion continued after the conference. They also received enormous attentions from the financial and securities institutions. This indicates BioFirst not only is Glory of Taiwan, and will have opportunity to become Glory of the world.

• < Prev
• Next >